Karolina Przybysz

Karolina Przybysz

Auto-generated profile, based on publicly available information

Karolina Przybysz

The PCK Maritime Hospital in Gdynia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ADAdela Dzwonkowska
Adela Dzwonkowska
JDJakub Dzwonkowski
Jakub Dzwonkowski
AKAlicja Kozłowska
Alicja Kozłowska
KPKarolina Przybysz
Karolina Przybysz
JRJarosław Rachoń
Jarosław Rachoń
NZNatalia Zienkiewicz
Natalia Zienkiewicz
Background: Artificial intelligence (AI) has become a promising tool in dermatology that could improve diagnostic accuracy, optimize clinical workflows, and expand access to dermatological care. Recent advances in machine learning and deep learning have enabled the development of highly accurate image-analysis systems, particularly for the diagnosis of skin lesions. However, the implementation of AI in clinical practice is accompanied by important ethical, legal, and equity-related challenges. Objective: This narrative review aims to summarize the current evidence regarding the applications of artificial intelligence in dermatology, with particular emphasis on its potential to improve healthcare accessibility, support teledermatology, and promote health equity while addressing existing limitations and ethical concerns. Methods: A narrative review of the literature was conducted using PubMed, PubMed Central, and Google Scholar. Peer-reviewed articles published in English between 2017 and 2025 were included. The literature was selected using keywords related to artificial intelligence, dermatology, skin cancer, teledermatology, and health equity. Results: The reviewed literature demonstrates that AI has achieved high diagnostic performance in the recognition of various skin diseases, particularly malignant skin lesions, and may significantly improve access to dermatological services through teledermatology and decision-support systems. Nevertheless, challenges including algorithmic bias, limited representation of diverse skin phototypes in training datasets, data privacy concerns, and insufficient regulatory frameworks remain substantial barriers to widespread implementation. Conclusions: Artificial intelligence has the potential to transform dermatological care by enhancing diagnostic efficiency and improving healthcare accessibility. However, its successful integration into clinical practice requires diverse and representative datasets, robust ethical and legal standards, and continued human oversight to ensure safe, equitable, and patient-centered healthcare.

3 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
LSLuiza Stadnik
Luiza Stadnik
AKAlicja Kozłowska
Alicja Kozłowska
KPKarolina Przybysz
Karolina Przybysz
NWNatalia Woroniecka
Natalia Woroniecka
ADAdela Dzwonkowska
Adela Dzwonkowska
JDJakub Dzwonkowski
Jakub Dzwonkowski
Background. Blood cortisol is a key biomarker of hypothalamic-pituitary-adrenal (HPA) axis activity and is widely used in sports science to assess physiological and psychological stress.However, its interpretation is limited by considerable biological variability and multiple influencing factors. Aim. To summarize current evidence on the physiological role of blood cortisol in endurance exercise and its usefulness for monitoring training load, recovery, and adaptation. Material and methods. A narrative review of peer-reviewed studies, systematic reviews,meta-analyses, and guidelines on cortisol physiology, exercise endocrinology, and athlete monitoring was conducted. Results. Blood cortisol reflects the physiological stress response and supports metabolic andimmune regulation during endurance exercise. Acute increases are a normal adaptive response, whereas persistent alterations may indicate excessive training stress when interpreted in context. Due to circadian variation and other confounding factors, single measurements have limited value. Current evidence favors longitudinal within-athlete monitoring combined with physiological, psychometric, hormonal, and performance measures.Conclusions. Blood cortisol is a useful component of endurance athlete monitoring butshould not be used as a stand-alone marker. Its greatest value lies in repeated standardized assessments interpreted within a multimodal monitoring approach. Key words: cortisol, endurance training, exercise physiology, training monitoring, trainingload, physiological stress, overtraining syndrome, athlete monitoring, Hypothalamic-Pituitary-Adrenal Axis

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
NZNatalia Zienkiewicz
Natalia Zienkiewicz
JRJarosław Rachoń
Jarosław Rachoń
ADAdela Dzwonkowska
Adela Dzwonkowska
JDJakub Dzwonkowski
Jakub Dzwonkowski
AKAlicja Kozłowska
Alicja Kozłowska
NSNicol Szerenos
Nicol Szerenos
Esophagectomy and gastrectomy for esophagogastric cancer are among the most physiologically demanding oncological operations and carry high rates of postoperative morbidity. Because neoadjuvant chemotherapy or chemoradiotherapy now precedes surgery in most patients with locally advanced disease, the preoperative interval offers an opportunity to intervene through multimodal prehabilitation, combining aerobic and resistance exercise, inspiratory muscle training, nutritional optimization, and psychological support. This narrative review synthesizes the rationale and current evidence for prehabilitation during the neoadjuvant window and, in particular, examines how it can be delivered in practice. Prehabilitation consistently improves preoperative functional capacity and respiratory muscle strength, and inspiratory muscle training is associated with fewer postoperative pulmonary complications, although effects on overall morbidity, length of stay, and mortality remain inconsistent. Beyond efficacy, the review foregrounds delivery and implementation: supervised hospital-based programmes are resource-intensive and geographically limiting, whereas home-based and digitally supported models — using smartphone applications, wearable sensors, and telehealth contact — offer a scalable alternative, with early evidence that home-based delivery may be comparable to supervised care. Technology-enabled prehabilitation raises its own questions of access and equity, including digital literacy and connectivity, that determine whether it narrows or widens existing disparities. Prehabilitation timed to the neoadjuvant window is a biologically plausible, feasible, and low-risk strategy to improve preoperative fitness; its translation into routine esophagogastric cancer care now depends as much on delivery model, technology, and implementation as on defining optimal clinical content, and standardized, adequately powered trials are needed to confirm benefit.

26 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
NSNicol Szerenos
Nicol Szerenos
DTDaria Trocka
Daria Trocka
NWNatalia Woroniecka
Natalia Woroniecka
LSLuiza Stadnik
Luiza Stadnik
KPKarolina Przybysz
Karolina Przybysz
NZNatalia Zienkiewicz
Natalia Zienkiewicz
Objective: The aim of this study is to analyze the current state of knowledge regarding the relationship between sleep deprivation and the risk of obesity progression, with particular emphasis on the underlying pathophysiological mechanisms and the therapeutic potential of interventions aimed at optimizing both the quality and duration of sleep. Materials and Methods: This review is based on an analysis of contemporary medical literature, including epidemiological data, meta-analyses of prospective cohort studies, and findings from experimental and clinical intervention studies published up to 2026. Results: The available body of evidence indicates a significant, non-linear J-shaped relationship between sleep duration and body mass index (BMI). Sleep lasting 7–8 hours per night is considered optimal for protection against excessive weight gain, whereas shorter sleep duration is associated with up to a 55% increase in the risk of obesity. The key mechanisms underlying this association include hormonal dysregulation within the ghrelin–leptin axis, characterized by elevated levels of the orexigenic hormone ghrelin and reduced levels of the satiety hormone leptin, resulting in direct stimulation of hunger centers. This phenomenon is accompanied by disturbances in energy homeostasis, manifested by an increase in daily energy intake of approximately 250–300 kcal without a corresponding compensatory increase in energy expenditure. At the metabolic level, reduced insulin sensitivity of peripheral tissues and a tendency toward preferential accumulation of intra-abdominal adipose tissue have been observed, promoting the development of visceral obesity. These processes are further amplified by neurobiological mechanisms, including heightened responsiveness of the brain’s reward system to highly caloric food stimuli, leading to impaired control over energy intake. Furthermore, evidence from intervention studies suggests that extending sleep duration in overweight individuals may result in a statistically significant reduction in spontaneous caloric consumption, averaging approximately 270 kcal per day. Conclusions: Sleep deprivation represents a significant, modifiable, and independent risk factor for obesity and its associated cardiometabolic disorders. In light of the available scientific evidence, routine assessment of sleep duration and quality should be incorporated into obesity diagnostic protocols. Sleep hygiene should be recognized as a third fundamental pillar of obesity prevention and treatment strategies, alongside dietary therapy and physical activity.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
NZNatalia Zienkiewicz
Natalia Zienkiewicz
JRJarosław Rachoń
Jarosław Rachoń
ADAdela Dzwonkowska
Adela Dzwonkowska
JDJakub Dzwonkowski
Jakub Dzwonkowski
AKAlicja Kozłowska
Alicja Kozłowska
NSNicol Szerenos
Nicol Szerenos
Medication non-adherence is a major challenge in modern healthcare, with approximately half of patients with chronic conditions failing to take medications as prescribed and global economic costs exceeding US$100 billion annually in the United States alone. Mobile health (mHealth) applications, of which over 97,000 are currently available on commercial platforms, offer a scalable approach to supporting adherence behaviours. This narrative review synthesises evidence published between 2018 and 2025 on the effectiveness of mHealth applications in chronic disease management, the behavioural mechanisms underpinning observed effects, and the socioeconomic barriers shaping equitable access, with particular attention to the European context. Peer-reviewed literature was identified through structured searches of MEDLINE, Scopus, and the Cochrane Library. Recent meta-analyses demonstrate consistent, moderate improvements in adherence, with pooled mean differences of 0.57 on the 8-item Morisky Medication Adherence Scale (95% CI 0.33–0.80) and absolute improvements of 15–20% on percentage-based measures across hypertension, type 2 diabetes, HIV, cardiovascular disease, and other chronic conditions. Effectiveness is mediated by reminder mechanisms, self-monitoring, social-support features, gamification, and educational content informed by behaviour change theory. However, populations with the highest baseline non-adherence — older adults, individuals with low health literacy, those of lower socioeconomic status, and patients in low- and middle-income countries — remain underserved by current applications, reflecting a persistent digital health equity gap. Within the European Union, the German Digital Health Applications framework and the forthcoming European Health Data Space provide important precedents for statutory reimbursement and interoperable digital health infrastructure.

8 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AKAlicja Kozłowska
Alicja Kozłowska
KPKarolina Przybysz
Karolina Przybysz
LSLuiza Stadnik
Luiza Stadnik
NZNatalia Zienkiewicz
Natalia Zienkiewicz
JRJarosław Rachoń
Jarosław Rachoń
NSNicol Szerenos
Nicol Szerenos
Background. Mastocytosis is a heterogeneous group of clonal mast cell disorders characterized by abnormal mast cell accumulation and activation in the skin, bone marrow, and other organs. Recent advances in molecular diagnostics and targeted therapies have significantly improved understanding of disease biology and management. Aim. This review aims to summarize current knowledge regarding the classification, pathophysiology, clinical manifestations, diagnosis, treatment, and prognosis of mastocytosis. Material and methods. A narrative review was performed by searching PubMed, Google Scholar, Scopus, and Medline for English-language articles. Precedence was given to current literature, clinical research, and international recommendations. Search terms included mastocytosis, systemic mastocytosis (SM), cutaneous mastocytosis (CM), mast cell, and KIT mutation. Results. Mastocytosis is classified into cutaneous mastocytosis, systemic mastocytosis, and mast cell sarcoma. Disease pathogenesis is primarily associated with activating KIT mutations, particularly KIT D816V, together with additional somatic mutations and microenvironmental factors contributing to disease heterogeneity and progression. Clinical manifestations result from mast cell mediator release and tissue infiltration. Diagnosis requires integration of clinical, histopathological, immunophenotypic, and molecular findings. Treatment strategies range from anti-mediator therapy in indolent disease to KIT-targeted therapies, including midostaurin and avapritinib, in advanced systemic mastocytosis. Conclusions. Mastocytosis remains a clinically diverse disorder requiring multidisciplinary diagnostic and therapeutic approaches. Advances in molecular characterization and targeted treatment have improved prognostic assessment and expanded therapeutic options, particularly in advanced disease.